In May 2021, Biogen exercised its option to acquire TMS-007 from TMS Co., Ltd., based on the promising Phase 2a data. This acquisition included an upfront payment and potential milestone payments, reflecting Biogen's commitment to advancing stroke therapies.

As of November 2024, TMS-007 is undergoing further clinical development to assess its efficacy and safety in treating acute ischemic stroke. The ongoing studies aim to establish its potential as a next-generation thrombolytic agent with an extended treatment window compared to current therapies.